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Abstract 
Injectable hydrogels offer promising tissue engineering approaches for vocal fold (VF) tissue repair. Research on VF tissue 
engineering scaffolds has largely been focused on derivatives of hyaluronan and collagen. Although chitosan hydrogels have 
been extensively investigated for various soft tissues, their potential use for VF tissue engineering has been overlooked. The aim 
of the present study was to investigate cross-linked Chitosan-glycol (GCs)/glyoxal (Gy) hydrogels for VFLP tissue engineering. 
The effects of Gy concentration on cell viability, viscoelastic properties, enzymatic degradation, and cell migration were studied. 
Six different groups of cell-seeded hydrogels, consisting of immortalized human vocal fold fibroblasts encapsulated in GCs/Gy 
hydrogels, were prepared to obtain target concentrations of 2×106 cells/ml, GCs 2% and Gy 0.02% (Group#1), 0.015% 
(Group#2), 0.01% (Group#3), 0.0075% (Group#4), 0.005% (Group#5), or 0.0025% (Group#6). The storage and loss moduli 
were 629±35Pa and 9±1 Pa, 560±28 Pa and 9±1Pa, 489±41 Pa and 8±1 Pa, 307±25 Pa and 4±1 Pa, 149±31 Pa and 3±1 Pa, 55±17 
Pa and 3±1 Pa for groups 1, 2, 3, 4, 5, and 6, respectively. The viability rates were above 90% for all groups, 3 hours after 
encapsulation. The viability rates were 60.0±2.2%, 80.3±2.2%, 83.5±0.5%, 83.1±1.3%, 88.2±0.1%, and 88.0±1.1% for groups 
1,2,3,4,5, and 6, respectively, one week after encapsulation inside GCs/Gy hydrogels. The average cell motility speed was 
0.09±0.03 μm/minute, 0.07±0.043 μm/minute, and 0.09±0.02 μm/minute for groups 4, 5, and 6, respectively. Following four 
weeks enzymatic degradation study, the mass loss was 10%, 21%, and 100% for groups 4, 5, and 6, respectively. Our results 
indicated that GCs/Gy hydrogels could be potential candidates for use in human VF tissue repair and regeneration.  
© 2015 The Authors. Published by Elsevier Ltd. 
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1. Introduction 
The human vocal folds (VFs), located within the larynx, include soft connective tissues, such as the epithelium, 
the basement membrane zone, and the lamina propria (LP). These tissues are attached to the vocalis muscle and 
anchored to the thyroid and arytenoid cartilages [1]. In normal phonation, the VF mucosa and ligament undergo 
vibrations at frequencies ranging from 20 Hz to 3 kHz and amplitudes of a few millimeters. Voice disorders can 
impose occupational risks especially for teachers, signers, and public speakers, and may also have emotional 
consequences.  
Scarring is a common voice disorder. Vocal fold scarring affects the mucosa and the LP. It may result from the 
surgical removal of benign or malignant VF lesions, phonotrauma or intubation over an extended period of time. 
Early scarring appears one to three months following VF injury, and may take up to twelve months for the 
remodeling phase completion and scarred VFLP maturation. Scarred VF tissue is fibrotic with diminished elastin but 
excessive disorganized collagen deposition [2]. As a result, the viscoelastic properties of the LP are significantly 
altered. Using a rabbit model, it was found that the stiffness and dynamic viscosity of the LP are one order of 
magnitude larger in scarred LP than in normal tissue [3]. Since the mechanical properties of the LP must be within a 
specific range to ensure proper phonation, viscoelastic biomaterials are often injected to treat scarring by 
compensating for the excessive stiffness of the scarred tissue. But, these materials degrade over time, and periodic 
re-injection is required. This shortcoming may be avoided through the use of tissue engineering approaches, which 
are intended to effectively modulate wound healing and regenerate functional VF tissue. The main motivation for the 
current investigation is to design, fabricate, characterize, and examine a new injectable biomaterial for VF tissue 
engineering.  
Injectable hydrogels offer promising tissue engineering approaches for VF tissue healing. Biomaterials based on 
natural hydrogels such as hyaluronic acid (HA), gelatin (Ge), chitosan, alginate and fibrin have been used to promote 
soft tissue regeneration [4-6]. Vocal fold tissue engineering investigations have been largely focused on derivatives 
of hyaluronic acid and collagen. These macromolecules are the main components of the VFLP extracellular matrix. 
Hyaluronic acid is a non-sulfated glycosaminoglycan and a major contributor to maintain VF tissue viscosity. The 
HA-Ge hydrogels cross-linked by disulfide bond formation are biocompatible [7] and has viscoelastic properties 
similar to VFLP [8]. The injection of HA-Ge hydrogels in rabbits after unilateral injury resulted in less fibrotic 
tissue. Favorable biomechanical properties were achieved compared to those of the controls injected with saline. One 
major problem with bulk HA-based hydrogels is their fast degradation in vivo. Alternatively, an injectable 
biomaterial based on densely cross-linked micro-gels of HA and Ge was developed [9], and was shown to be 
biocompatible in a preliminary animal study [10]. 
Chitosan is a linear poly-saccharide containing heteropolymer of randomly distributed β-(1,4)-linked ᴅ-
glucosamine and N-acetyl-ᴅ-glucosamine units [11]. Chitosan, derived from chitin by partial deacetylation, is the 
second most abundant natural biopolymer [12]. Similarities to glycosaminoglycans, abundance in nature, 
biocompatibility, low production cost, and low immune-stimulatory activities have made this polymer very 
appealing for drug delivery, wound healing, and tissue engineering applications [13]. Chitosan is biodegradable, and 
can be metabolized by certain human enzymes, especially lysozyme. Chitosan hydrogels have extensively been 
investigated for variety of soft tissues such as skin [14], cartilage [15], blood vessels [16], and brain [17]. However, 
they have not been investigated for their potential use in VF tissue engineering. 
Ionic and covalent cross-linking are the most common methods for the fabrication of chitosan hydrogels. 
Covalent cross-linking forms a permanent network, and therefore the hydrogels may reside longer in vivo, thereby 
better for tissue engineering applications. Ionic cross-linking, in contrast, is more prone to break down with the body 
fluids, and is then more appropriate for drug delivery applications [18]. 
The aim of the present study was to investigate cross-linked Glycol Chitosan (GCs)/glyoxal (Gy) hydrogels for 
VFLP tissue engineering applications. The effects of cross-linker (Gy) concentration on cell viability, viscoelastic 
properties, enzymatic degradation, and cell migration kinematics were studied.  
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2. Materials and Methods 
2.1. Cell Culture in Flask 
Immortalized human VF fibroblasts (I-HVFFs) were cultured in a mixture of Dulbecco’s Modified Eagle 
Medium (Life Technologies Inc., Burlington, ON), 10% fetal bovine serum (Sigma-Aldrich Corporate, St. Louis, 
MO), 1% Penicillin/Streptomycin (Sigma-Aldrich Corporate), and 1% MEM non-essential amino acids (Sigma-
Aldrich Corporate) at 37ºC, in 5% CO2 humidified atmosphere. The cell culture medium (CCM) was replaced every 
three days. Cells were disassociated using 0.25% trypsin-EDTA when the cell confluency reached 70%.  
2.2. Cell-Seeded Hydrogel Preparation 
Glycol-Chitosan and Glyoxal 40% were purchased from Sigma Aldrich Corporate. Solutions of GCs 4% and Gy 
10% in deionized water were prepared, and placed in a rugged laboratory rotator (Glas-Col Corporate, Terre Haute, 
IN) at 30 rpm for 24 consecutive hours. The solutions were subsequently autoclaved to avoid contamination. Six 
different groups of cell-seeded hydrogels were prepared to obtain target concentrations of 2×106 cells/ml, GCs 2%, 
and Gy 0.02% (Group#1), 0.015% (Group#2), 0.01% (Group#3), 0.0075% (Group#4), 0.005% (Group#5), or 
0.0025% (Group#6).  
2.3. Rheometry 
A TA Instrument Rheometer-AR2000 (New Castle, DE) was used to measure the shear elastic and loss moduli of 
the hydrogels at room temperature. Parallel plates with a diameter of 20 mm and a gap of 200 μm were used. The 
samples were prepared and molded to be cylindrical in shape, nominally 20 mm in diameter and 1.5 mm in 
thickness. The samples were sealed and kept at 37ºC, in humidified atmosphere for 24 hours. They were then 
properly placed to fill the gap between the plates. They were surrounded by water in order to prevent dehydration. A 
controlled stress frequency sweep test was performed for the frequency range between 0.5 Hz and 5 Hz.  
2.4. Enzymatic Degradation 
The enzymatic degradation of the hydrogels was investigated using lysozyme in PBS 1X for hydrogels with the 
three lower concentrations of Glyoxal (0.0075% (Group#4), 0.005% (Group#5), or 0.0025% (Group#6)). A volume 
of 0.5 ml GCs-Gy was poured in each vial. PBS 1X (1 mL) was added into the vials two hours after preparation. The 
vials were then placed inside a humidified atmosphere at 37ºC, and gently agitated at 75 rpm. The medium was 
changed every eight hours. After 24 hours, the medium was removed, and the hydrogel weight was measured. The 
hydrogels were then incubated in the solution of 13.0 μg/ml lysozyme in PBS 1X, with gentle mechanical agitation 
at 75 rpm over the period of study. This lysozyme concentration corresponds to that in human serum [19] . The 
solution was refreshed daily to ensure continuous enzyme activity. After three days, one week, two weeks, and one 
month, the medium was removed carefully, the samples were lyophilized, and the dry weights of the hydrogels were 
measured. The weight of the dried hydrogels was calculated by subtraction of the empty vial weight from the 
measured data. The remaining weight fraction, i.e., Wτ/W0 in which W0 is the original dry weight of the hydrogels, 
and Wτ is the associated dry weight at time τ, was computed and plotted with respect to time. The extent of in 
vitro degradation was expressed as the weight fraction remaining of the dried hydrogels at the specific time intervals, 
i.e., Wτ/W0.   
2.5. Cell Viability 
The LIVE/DEAD® Viability/Cytotoxicity kit (Life Technologies Inc., Burlington, ON) was used to assess the 
viability of cells in the hydrogel samples at the following time points: three hours, three days, and a week after 
preparation. The kit provides a two-color fluorescent image. Calcein-AM and Ethidium homodimer-1 (EthD-1) 
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specifically stain live and dead cells, respectively. The samples were washed for 3u5 minutes (i.e., three times, each 
for 5 minutes) using 1X Phosphate-buffered saline (PBS). They were then incubated with working solution (2 μM 
calcein-AM and 4 μM EthD-1 in DPBS (Life Technologies Inc., Burlington, ON)) for 30 minutes in darkness at 
room temperature. The samples were washed again in 1X PBS for 3u5 minutes. An inverted confocal fluorescence 
microscope (LSM710, Zeiss, Jena, Germany) was used to image the stained samples. All the images were acquired 
using a 10X objective (10x/0.45 Dry Plan-Apochromat, Zeiss). Series of XY images, called Z-stack, were obtained. 
Image acquisition and image analysis were performed using the software Zen (Zeiss) and Imaris version 7.5.6 
(Bitplane, South Windsor, CT), respectively. The viability rate was then obtained by dividing the number of the live 
cells to the total number of cells (the number of both live and dead cells) in each reconstructed image. The 
normalized number of cells was then obtained by dividing the number of cells (live and dead) with the volume of the 
reconstructed image. 
2.6. Migration 
Vybrant® DiD Cell-Labeling Solution (Life Technologies Inc.) was used to stain the cell membrane. The cells 
were disassociated using 0.25% trypsin-EDTA. They were subsequently centrifuged and suspended in serum-free 
CCM. 5μl of the labelling solution was added to each 1×106 cells. The cell solution was then incubated at 37ºC for 
20 minutes. It was then centrifuged for 5 min at 1.5×103 rpm. The solution was then replaced with serum-free CCM, 
and pipetted up and down to mix thoroughly. The solution was again centrifuged, and replaced with serum-free 
CCM. The labelled cells were used to prepare cell-mixture solutions to obtain target concentrations of 5×105 
cells/ml, GCs 2%, and Gy 0.0075% (Group#4), 0.005% (Group#5), or 0.0025% (Group#6). An inverted confocal 
fluorescence microscope (LSM710, Zeiss) was used to image each sample for four consecutive hours. Image 
analysis was performed using Imaris version 7.5.6 (Bitplane).  
3. Results and Discussion 
3.1.  Cell Viability 
Representative images of viability tests for group#2, group#4, and group#6 are shown in Fig. 1. The results 
indicated that the high concentration of Glyoxal cross-linker can cause cytotoxicity to human fibroblast cells, as 
shown in Fig. 2. Glyoxal was not cytotoxic up to three hours after mixing with the cells for any of the groups under 
investigation. However, group #1 and to some extent group #2 showed significant cytotoxicity after three days. 
Glyoxal is a reactive α-oxoaldehyde and works as glycating agent in all tissues and body fluids in physiological 
conditions. Glyoxal is capable of inducing significant cellular damage above 5 mM (0.025%) by oxidative stress 
[20]. All of the studied groups had concentration below 0.025%. Not surprisingly, the group#1 with glyoxal 
concentration of 0.02% had still exhibited toxicity after three days. The concentration of glyoxal under physiological 
condition is around 12.5 μg/ml (0.00125%) [21], which is lower than that of the groups studied. It should be noted 
that glyoxal cross-linking with chitosan starts immediately after blending the ingredients and the cell solution. This 
lowers the concentration of free glyoxal in the mixture, and mitigates its cytotoxic effects. Furthermore, glyoxal is 
detoxified enzymatically by cytosolic glyoxalase system [20].   
3.2. Rheology 
Shear storage and loss moduli of the fabricated hydrogels are shown in table 1. An increase in the Gy 
concentration yielded greater storage and loss moduli. Fine-tuned viscoelastic properties of injectable biomaterials 
are essential to restore the functionality of differentiated VF tissue. The VFLP undergoes complex mechanical 
loading during phonation, which influences the structural and functional properties of the VF tissue during 
development [22]. In a study using a phono-mimetic bioreactor, it was shown that the mechanical properties of the 
injectable biomaterials have a significant impact on onset phonatory characteristics [23]. 
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Fig. 1. Fluorescence images of I-HVFFs in the Cs-Glayoxal hydrogel. Viable cells are green-fluorescent and dead cells are red-fluorescent, 
respectively.  
 
 
Fig. 2. (a) Viability rates of six chitosan/glyoxal hydrogel groups with different cross-linking concentrations. (b) Normalized total number of cells 
per volume unit (μm3) in the groups. 
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The injectable biomaterials that are stiffer than the surrounding tissue may also shield stress and impede the 
proper mechanotransduction necessary for extracellular matrix remodeling during in vivo tissue regeneration. On the 
other side, very soft hydrogels may lead to excessive mechanical stress on fibroblast cells. This may stimulate the 
generation of smooth muscle actin (SMA) positive myofibroblasts [24] and result in scarred tissue formation. 
Therefore, the amount of the mechanical stress experienced by the cells can be effectively modulated by the 
viscoelastic properties of the injectable biomaterial [25]. The shear viscoelastic properties of the CS hydrogels (table 
1) were in the range of those of human [26]  and pig [27] VFLP and below those of rabbit [28] and rat [29] VFLP 
tissues. In particular, the storage shear moduli of human VFLP were between 10-250 Pa and 10- 100 Pa for male 
and female subjects, respectively. Our measurements indicate that the groups 4, 5, and 6 mimic the shear storage 
modulus of male VFLP, and groups 5 and 6 mimic that of female VFLP. Since groups 4, 5, and 6 were also shown 
to have favorable cellular viability, these groups were selected for the remainder studies, i.e., migration and 
degradation studies.  
 
Table 1. Viscoelastic properties of GCs/Gy hydrogels from shear rheometry measurements. 
Group number (Gy concentration) Storage shear modulus (Pa) Loss modulus (Pa) 
#1 (0.020%) 629±35 9±1 
#2 (0.015%) 560±28 9±1 
#3 (0.010%) 
#4 (0.005%) 
#5 (0.005%) 
#6 (0.0025%) 
489±41 
307±25 
149±31 
55±17 
8±1 
4±1 
3±1 
3±1 
 
3.3. Cell migration 
The cell migration speed as well as the total displacement of the cells during 4 hours imaging is shown in Fig. 3. 
Their storage shear modulus is in the range of that of human VFLP. The average cell speed was similar between the 
groups 4, 5, and 6. The ability of the cell to move freely inside the GCs/Gy hydrogel will allow cells to migrate into 
the injectable scaffolds from the surrounding tissue. The disability of cells to move into the matrix may result in 
foreign body reaction and fibrous capsule formation around the injected biomaterial [30]. These results confirm the 
ability of cells to move inside the Cs hydrogels. This characteristic can potentially be used to recruit patients own 
cells from the surrounding tissue.   
 
 
Fig. 3. Cell migration results for groups 4, 5, and 6 with Glyoxal concentrations of 0.0075%, 0.005%, 0.0025%, respectively. (a) Average 
displacement of the I-HVFFs in three hydrogel groups. (b) The associate average speed. 
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3.4. Enzymatic degradation  
The degradation profile for groups 4, 5, and 6 are shown in Fig. 4. Group 6 completely degraded in four weeks 
with half-life of 18 days. The degradation rate slows down significantly with the increase of cross-linker 
concentration. Group 4 and 5 degraded much slower compared to group 6. Following 4 weeks incubation in the 
enzyme solution, 10% and 21% of the hydrogel groups 4, and 5 degraded, respectively. The degradation profile 
should be commensurate with the formation of neo-LP tissue. However, no standard evaluation criterion exists to 
assess the degradation rate of the scaffolds for VFLP tissue regeneration. We estimate that a total degradation time 
between one to three months is required. This time period is correlated with the end of inflammation and granulation 
tissue formation, and varies across individuals. We speculate that one to three months residence of the scaffold 
material is crucial for its constant interactions with patients’ cells, such as macrophages and fibroblast cells. These 
interactions are intended to modulate wound healing towards scar-free neo-LP tissue regeneration.  
4. Conclusion 
Glycol chitosan/glyoxal hydrogels with lower concentrations of Gy (≤0.0075%) were shown to support the 
fibroblast cells viability, and their viscoelastic properties were in the range of those of human VFLP. It was shown 
that by tuning the concentration of the Gy cross-linker, the degradation time of over one month was achieved. The 
VF fibroblasts were observed to move freely inside the GCS/Gy hydrogels. In conclusion, the GCs/Gy hydrogels are 
potential candidates for VF tissue regeneration. 
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